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ABSTRACT
Solid tumours vary in sensitivity to the vascular disrupting agent combretastatin 
A-4 3-O-phosphate (CA4P), but underlying factors are poorly understood. The 
signaling sphingolipid, sphingosine-1-phosphate (S1P), promotes vascular barrier 
integrity by promoting assembly of VE-cadherin/β-catenin complexes. We tested the 
hypothesis that tumour pre-treatment with S1P would render tumours less susceptible 
to CA4P.
S1P (1μM) pretreatment attenuated an increase in endothelial cell (HUVEC) 
monolayer permeability induced by 10μM CA4P. Intravenously administered S1P 
(8mg/kg/hr for 20 minutes then 2mg/kg/hr for 40 minutes), reduced CA4P-
induced (30mg/kg) blood flow shut-down in fibrosarcoma tumours in SCID mice 
(n≥7 per group), as measured by tumour retention of an intravenously administered 
fluorescent lectin. A trend towards in vivo protection was also found using laser 
Doppler flowmetry. Immunohistochemical staining of tumours ex vivo revealed 
disrupted patterns of VE-cadherin in vasculature of mice treated with CA4P, which 
were decreased by pretreatment with S1P. S1P treatment also stabilized N-cadherin 
junctions between endothelial cells and smooth muscle cells in culture, and stabilized 
tubulin filaments in HUVEC monolayers.
We conclude that the rapid shutdown of tumour microvasculature by CA4P is 
due in part to disruption of adherens junctions and that S1P has a protective effect 
on both adherens junctions and the endothelial cell cytoskeleton.
INTRODUCTION
Tumour blood vessels tend to be disorganized, 
immature and hyperpermeable, with the result that tumour 
microvasculature has become a key target in anti-cancer 
therapy. The tumour vascular disrupting agent (VDA) 
combretastatin A-4 3-O-phosphate (CA4P; fosbretabulin) 
is a microtubule-binding agent, which induces rapid and 
selective tumour vascular shutdown and secondary tumour 
cell death [reviewed in 1,2]. It is currently in phase I-III 
clinical trials in combination therapy, most notably with 
bevacizumab, in a variety of tumour types (http://www.
mateon.com/) [3-6]. The heightened sensitivity of tumour-
associated blood vessels to CA4P is not fully understood. 
Although these vessels have a relatively high endothelial 
cell proliferation rate compared to those of normal tissues 
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[7-9] and CA4P has anti-proliferative effects on dividing 
endothelial cells after prolonged exposure [10], the 
differences in proliferative capacity cannot account for the 
rapid blood flow shutdown observed in tumours following 
VDA administration [11]. The relatively short plasma half-
life of CA4P (~22 minutes) suggests that morphological 
and functional effects upon the cytoskeleton rather than 
cytotoxicity mediate the in vivo effects of CA4P on tumour 
blood flow [11]. The main aim of the current study was 
to investigate how the stability of vascular endothelial 
cadherin (VE-cadherin)-associated endothelial cell 
junctions in tumors influences the rapid tumor vascular 
response to CA4P.
Endothelial shape and function are maintained by 
the cytoskeleton, a key target for tubulin-binding VDAs 
[12]. CA4P was found to induce actin stress fibres, focal 
adhesions and an increase in permeability of endothelial 
cell monolayers in culture, triggered by microtubule 
disruption and mediated by the small GTPase Rho and Rho 
kinase [12, 13]. Furthermore, a CA4P-induced increase in 
solid tumour vascular permeability has been implicated in 
the drug’s mechanism of action in vivo [14]. Intercellular 
adherens junctions are critical in maintaining vascular 
integrity and it is well established that the permeability 
of the endothelium is regulated by the endothelial cell-
specific adherens junction molecule, vascular endothelial 
cadherin (VE-cadherin), which directly links endothelial 
cells to the actin cytoskeleton [15-18]. This interface is 
maintained via the interactions of the cytoplasmic domain 
of VE-cadherin with 3 related proteins (β-catenin, p120 
and plakoglobulin) anchored to the actin cytoskeleton [15]. 
Vincent et al hypothesized that CA4P disrupts the VE-
cadherin/β-catenin association, required for endothelial 
cell adhesion and survival during neovessel assembly and 
re-modeling, which may lead to rapid vascular collapse 
and tumour necrosis [17]. This rapid disengagement of 
the VE-cadherin/β-catenin complex and consequential 
rearrangement of the cytoskeleton would provide an 
explanation for both the immediate induction of CA4P-
mediated vascular collapse and the later cytotoxic effects 
of the agent. Differences in the stability of VE-cadherin 
junctions or its association to these proteins could explain 
variations in endothelium permeability, and therefore why 
different tumours and cell lines display varying levels of 
susceptibility to CA4P.
N-cadherin is an additional adherens junctional 
protein, which is expressed on both endothelial cells 
and mural cells including pericytes and vascular smooth 
muscle cells (SMC). In the vasculature, it is involved in 
intercellular adhesion interactions between endothelial 
cells and mural cells [19]. Since investiture of pericytes 
to the tumour vasculature is important in vascular 
stabilization and maturation, it is possible that CA4P 
targets N-cadherin mediated intercellular junctions in 
addition to endothelial cell - endothelial cell interactions 
in the process of vascular destabilisation.
Sphingosine-1-phosphate (S1P) is a bioactive lipid 
mediator released, for example, at sites of endothelial 
injury by cells including activated platelets, and has been 
implicated in numerous cancer pathways [20]. It exerts 
its effects by binding to the G-protein coupled receptors 
S1P1-5 [21], which are expressed in a tissue-specific 
manner. Endothelial cells display the receptor S1P1, and 
ligation of S1P to S1P1 at physiological concentrations 
(10 nM – 2 μM) elicits a variety of responses, including 
the enhancement of barrier function by stimulation 
of Rho- and Rac-dependent assembly of adherens 
junctions [22]. S1P induces the enhancement of VE-
cadherin interactions with ɑ- and β-catenin [23] and the 
translocation of VE-cadherin to endothelial cell junctions 
[21]. In the mesenteric microvasculature in situ, S1P 
was shown to stabilize the vasculature against an acute 
increase in permeability by preventing the rearrangement 
of VE-cadherin, via Rac-dependent pathways, that 
was otherwise induced by platelet activating factor or 
bradykinin [24]. Indeed, degradation of the receptor S1P1 
(by a phosphorylated derivative of FTY720, an analogue 
of S1P), thereby preventing S1P signaling, resulted in 
vascular leak in mice [25].
Here, we hypothesised that disruption of tumour 
adherens junctions is a primary mechanism of action 
for CA4P in vivo, triggering blood flow reduction, and 
that this disruption could be attenuated by pretreatment 
with sphingosine-1-phosphate (S1P). We used a mouse 
fibrosarcoma cell line, fs120, which expresses the 
VEGF120 isoform of vascular endothelial growth factor 
A (VEGF-A) in isolation [26]. Solid fs120 tumors are 
characterized by an immature leaky vasculature with little 
pericyte investiture, which is prone to haemorrhage and 
sensitive to CA4P treatment [26]. We demonstrate the 
effect of CA4P on VE-cadherin adherens junctions in vivo 
in fs120 tumours, using immunofluorescence staining 
for VE-cadherin on frozen tissue sections. We stabilized 
junctions prior to CA4P insult both in vitro and in vivo 
by pre-treatment with S1P. To establish the effects of 
combined S1P and CA4P treatment on tumour perfusion 
in vivo, we monitored changes in red cell flux within fs120 
tumours of live animals following treatment and measured 
a ‘tumour perfusion index’ in excised tumours ex vivo. We 




HUVEC grown to confluence on gelatin coated 24 
well inserts (3 μm pore size) in 24 well plates remained 
as intact monolayers after vehicle or S1P treatment (Figure 
1A-1B), whereas treatment with CA4P resulted in cell 
retraction and disruption of the monolayers, with visible 
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gaps formed between the cells (Figure 1C). Cell retraction 
was attenuated in cultures pre-treated with S1P (Figure 1D).
Untreated cell monolayers, or monolayers treated 
with 1 μM S1P alone were the least permeable. Treatment 
with a higher dose (10 μM) of S1P tended to increase 
the permeability of the monolayer but the increase was 
not significantly different from controls. Treatment with 
10 μM CA4P increased permeability of the monolayers 
as expected compared to either vehicle alone or S1P 
treatment (p=<.001). Pre-treatment of cells with 1 μM 
S1P decreased the 10 μM CA4P-induced permeability 
(p=0.028) (Figure 1E). These results concurred with the 
qualitative image data.
Measurement of red cell flux within fs120 
tumours in vivo
Laser Doppler flowmetry enabled rapid changes 
in tumour microvascular red cell flux to be measured 
longitudinally before/after treatment, expressed as 
blood perfusion units (BPU, Figure 2). Changes were 
measured in fs120-bearing mice from four treatment 
groups: S1P vehicle & CA4P vehicle (VEH+VEH; n=9), 
S1P vehicle & CA4P (VEH+CA4P; n=18), S1P & CA4P 
(S1P+CA4P; n=16), S1P & CA4P vehicle (S1P+VEH; 
n=7). Laser Doppler results showed a sudden drop in 
BPU within minutes after administration of CA4P (30 
mg/kg) as expected, which was attenuated, although not 
significantly, by the prior treatment of animals with S1P. 
Overall, there was a significant effect of time on laser 
Doppler signal (P<0.0001) but the effect of treatment did 
not reach significance (P=0.123). The gradual decrease 
in BPU (after an initial rise in the first 20-30 minutes) in 
the vehicle treated and S1P treated groups may relate to 
anaesthesia-related cardio-respiratory depression over this 
time period.
A trend for a protective effect of S1P administration 
on CA4P-induced vascular disruption using laser Doppler 
flowmetry encouraged further investigation using CD31/
lectin staining of CA4P and S1P & CA4P treated tumours 
to calculate the tumour perfusion index. CD31+ and lectin+ 
areas were measured in stained ex vivo tumour sections 
Figure 1: CA4P induced permeability of HUVEC monolayers is ameliorated by pretreatment with S1P. (A-D), HUVEC 
monolayers treated with (A) saline, (B) 10 μM S1P, (C) 10 μM CA4P or (D), 10 μM S1P plus 10 μM CA4P. Gaps in the cell monolayer 
are clearly visible after treatment with CA4P (C), which are either diminished or not present when cells were pre-treated with S1P (D). 
(E) HUVEC permeability assay using passage of FITC-dextran through the monolayers as a marker of permeability. Cell monolayers and 
gelatin are negative and positive controls respectively, for FITC dextran egress. Experiments were performed in triplicate three times, and 
results are means ±SEM. ***p<0.005, *p<0.05.
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and lectin+ areas expressed as a percentage of CD31+ 
areas. Lectin+/CD31+ areas were significantly more 
prevalent in tumours pre-treated with S1P prior to CA4P 
administration than those treated with CA4P alone (Figure 
3), indicating a higher degree of microvascular collapse in 
CA4P treated tumours without S1P pre-treatment.
VE-cadherin staining patterns in tumours ex 
vivo following Laser Doppler flowmetry
Following Laser Doppler flowmetry, tumours were 
excised from the mice from all four treatment groups, 
sectioned, and stained for VE-cadherin. Tumours from 
mice treated with CA4P showed significantly more 
disruption in VE-cadherin staining than those treated 
with vehicles, S1P or S1P followed by CA4P (Figure 4A-
4D). Image analysis reveals that only ~30% VE-cadherin 
staining remained intact in CA4P treated tumours versus 
65-75% in S1P or vehicle treated. Pretreatment with S1P 
prior to administration of CA4P increased intact VE-
cadherin staining to ~60% of total staining, comparable to 
vehicle or S1P treated tumours (Figure 4E). It was noted 
that microvessels found centrally within the tumour mass 
generally displayed more disrupted VE-cadherin staining 
after CA4P treatment than those at the tumour periphery 
(Supplementary Figure 1).
Flow cytometry of S1P/CA4P treated HUVEC
To determine whether CA4P treatment results in 
a loss of VE-cadherin expression from the cell surface, 
adherent HUVEC were treated +/- CA4P, with or without 
S1P pre-treatment, then detached from the tissue culture 
plastic and stained in suspension for extracellular VE-
cadherin and analysed by FACS. The results showed no 
difference in total surface expression of VE-cadherin 
between the treatment groups (Figure 5A) suggesting that 
the spatial rearrangement of the VE-cadherin following 
CA4P treatment is responsible for the increased monolayer 
permeability observed in vitro and not a loss of surface 
Figure 2: In vivo Laser Doppler measurement of blood flow in tumours following treatment with S1P/CA4P. Blood 
perfusion units (BPU) were measured using Laser Doppler flowmetry in fs120 tumour-bearing mice from 4 treatment groups. Results are 
shown as a percentage of values at time 0, when S1P or S1P vehicle infusion was started (see main text for details). Points represent mean 
± SEM for n=9 animals for the vehicle only treated group (VEH+VEH), n=7 for the S1P treated group (S1P+VEH), n=18 for the CA4P 
treated group (VEH+CA4P) and n=16 for the S1P+CA4P group.
Oncotarget5www.impactjournals.com/oncotarget
localized VE-cadherin. To visualize whether this was 
indeed the case, HUVEC were grown to confluence on 
4-chamber slides and treated with CA4P either with or 
without S1P pre-treatment and stained for VE-cadherin. In 
untreated cells, VE-cadherin expression is localized to the 
outer edges of the cells (Figure 5B, top left), whereas 60 
min after CA4P treatment the VE-cadherin redistributed 
into a zigzag pattern (arrowheads) (Figure 5B, top right), 
a feature which was not as prominent when cells were 
pretreated with S1P (Figure 5B, bottom right). This visible 
redistribution of VE-cadherin following CA4P treatment 
is consistent with previous results [15]. The change in 
expression pattern was also evident after only 10 min 
CA4P treatment (Figure 5B, top middle), which again 
was curtailed by S1P pre-treatment (Figure 5B, bottom 
middle). S1P treatment alone had no visible effect on VE-
cadherin staining (Figure 5B, bottom left).
S1P stabilizes microtubules as well as VE-
cadherin junctions
The primary action of CA4P on endothelial cells is to 
depolymerize tubulin, which triggers actin re-organisation 
into stress fibres, actinomyosin contractility and formation 
of focal adhesions [12]. HUVEC monolayers were stained 
for either tubulin or VE-cadherin following different 
incubation times with 1 μM CA4P (2-10 minutes) to 
obtain a time-course of tubulin and VE-cadherin effects 
(Figure 6A-6H). Results showed no effects on either the 
tubulin cytoskeleton or VE-cadherin junctions for 2 or 4 
minute incubation times (4 minute incubation results are 
shown in Figure 6A and 6E). However, both disruption 
of microtubules and early spatial rearrangement of VE-
cadherin were observed for 8 or more minutes (Figure 6B 
and 6F; 6C and 6G) and both tubulin and VE-cadherin 
were stabilized by pretreatment with S1P (Figure 6D and 
6H respectively).
S1P protects against N-cadherin junction 
disruption by CA4P
Investiture by mural cells, such as pericytes, is 
important in the stabilisation of vasculature. The adherens 
junctional protein N-cadherin is typically located at 
intercellular junctions between EC and mural cells 
(pericytes, SMC) as well as EC/EC junctions. We co-
cultured HUVEC with human vascular SMC (vSMC) 
and treated them with CA4P, with or without S1P pre-
Figure 3: Vascular collapse by measurement of lectin/CD31 staining. (A) Representative images of staining for CD31 (red) and 
lectin (green) in tumours treated with CA4P alone or pre-treated with S1P. Merged images reveal fewer perfused vessels in the CA4P treated 
tumour than in the tumour treated with S1P+CA4P, as indicated by a paucity of lectin staining relative to CD31+ (vascular endothelial) cells 
(B) Perfusion index calculated as the number of pixels stained+ve for FITC-lectin as a % of the number of pixels stained +ve for CD31 for 
whole data sets in tumours treated with CA4P or S1P+CA4P. Rectangles in the low power images indicate the location of the corresponding 
high power images. Points and bars represent means ± SEM for n = 7-8 mice. * p<0.05.
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treatment, then used immunofluorescence to localize 
N-cadherin. Untreated co-cultured HUVEC and vSMC 
that were stained for CD31 (indicating endothelial 
cells) and N-cadherin (indicating EC/SMC junctions) 
displayed smooth, intact CD31 and N-cadherin staining 
at intercellular junctions and cell peripheries, with some 
cytoplasmic N-cadherin apparent (Figure 7A, 7C, 7E). 
Tubule structures formed from around 40% of the co-
cultured cells (the remainder presented as flat monolayers). 
Treatment for 10 min with 1μM CA4P caused a loss of 
visible N-cadherin from the cell-cell junctions in the 
tubule formations (comparing Figure 7C and 7D). CA4P 
treatment did not appear to affect CD31 distribution, 
whereas N-cadherin staining appeared intracellular and 
punctate following CA4P treatment (comparing Figure 
7E and 7F, Supplementary Figure 2). The change in 
N-cadherin localisation following CA4P treatment 
was blocked by pre-treatment with 1μM S1P, although 
staining was not so smooth, an effect also observed for 
treatment with S1P alone (Figure 7G). Supplementary 
Figure 2 shows N-cadherin staining for endothelial cell 
only monolayers. Here, there was no peripheral staining, 
confirming that peripheral staining in the co-cultures was 
due to endothelial-vSMC interactions.
DISCUSSION
We hypothesized that stabilization of the 
microvasculature of fs120 tumours by administering 
S1P would make them less susceptible to CA4P. In vitro, 
endothelial cell monolayers were less permeable after 
CA4P treatment when pre-treated with S1P, and VE-
cadherin staining of CA4P treated HUVEC demonstrated 
a surface rearrangement of VE-cadherin, which was 
Figure 4: VE-cadherin staining patterns in fs120 tumours excised following S1P/CA4P treatment. Tumours were excised 
from mice treated with vehicles (A), S1P vehicle + CA4P (B) S1P + CA4P (C) or S1P + CA4P vehicle (D), as described in Methods, and 
immunofluorescently stained for VE-cadherin. Staining appears smoother and more intact in (A), (C) and (D). Representative images 
shown from at least five images per tumour; Images show 2D-projections from 3D confocal images viewed using a 40x objective lens. 
Areas of smooth, intact VE-cadherin were measured as a percentage of total stained area in five images per tumour (E). Data are means ± 
SEM for the number of tumours shown. * = p<0.05, *** = p<0.005. Scalebars = 40μm.
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Figure 5: CA4P treatment does not alter the quantity of VE-cadherin expressed on HUVEC cell surfaces. FACS 
analysis of S1P/CA4P treated HUVEC labelled for VE-cadherin reveals that there is no statistical significance in level of expression of 
extracellular VE-cadherin on treated HUVEC monolayers (A). Bars represent means ± SEM for 3 repeated experiments. Fluorescence 
immunohistochemistry using an antibody against VE-cadherin on treated HUVEC monolayers shows that extracellular VE-cadherin 
expression is ‘re-arranged’ rather than downregulated (B). In untreated or S1P-treated cells, VE-cadherin expression is localized to the 
outer edges of the cells, whereas 10 min after CA4P treatment the VE-cadherin is rearranged into a zigzag pattern (arrowheads), an effect 
which is decreased by pretreatment with S1P. The change in expression is more prominent after 60 min CA4P treatment but again the effect 
is somewhat curtailed by S1P pre-treatment. Scalebars = 5 μm.
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prevented by pre-administration of S1P. Following these in 
vitro experiments, we showed a trend towards S1P infusion 
reducing the in vivo drop in laser Doppler flowmetry signal 
caused by CA4P treatment alone. Convincing evidence 
for S1P pre-treatment imparting a degree of protection 
to the tumour vasculature against CA4P-induced 
shutdown was provided by intravenous administration 
of fluorescent lectin to calculate a tumour perfusion 
index. Furthermore, fluorescent immunohistochemical 
staining of the vasculature from these tumours showed 
that in vivo, pre-treatment with S1P did indeed stabilize 
VE-cadherin on adherens junctions. Laser Doppler 
flowmetry is an invasive technique, which cannot readily 
discriminate between viable and necrotic regions within 
tumors and only samples a few locations within each 
tumour. Less invasive techniques that provide relatively 
high resolution tomographic images of tumor vascular 
function, such as Doppler ultrasound, dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) or 
emerging modalities such as high resolution multispectral 
optoacoustic tomography (MSOT) [27] would be useful 
in future studies to investigate the tumor microcirculation 
in its entirety. Our observation that CA4P has a greater 
effect upon the smaller microvessels deeper within the 
tumour mass than the larger vessels found at the tumour 
periphery is confirmatory of previous data on the action of 
CA4P [11]. The fact that pre-treatment of mice with S1P 
could not completely block the CA4P-induced reduction 
in tumour perfusion could be down to a number of factors. 
For instance, complete protection of VE- and N-cadherin 
junctions may not have been achieved. In addition, part of 
the vascular shut-down instigated by CA4P is likely to be 
due to other mechanisms such as a direct vasoconstrictive 
effect on tumour-supplying arterioles [28-29].
The sphingolipid S1P has recently been gaining 
interest as it plays several roles in both inflammation 
and cancer-related pathways [20]. Whilst ligation of S1P 
to its receptor S1P1 at concentrations of 10 nM – 2 μM 
enhances barrier function by stimulating assembly of 
adherens junctions [22], Shikata et al showed that in vitro, 
binding of high concentrations of S1P (>5 μM) to S1P1 
results in active cytoskeletal rearrangement, stress fibre 
formation and disruption of endothelial barrier integrity 
[30]. In the current study, 1 μM S1P tended to be more 
protective than 10 μM S1P against 10 μM CA4P (Figure 
1E), consistent with this previous finding.
S1P has been shown to stabilise vasculature via 
adherens junctions by inducing the translocation of VE-
cadherin to endothelial cell junctions [21] and preventing 
the platelet activating-factor induced rearrangement of 
VE-cadherin [24]. A recent study investigating barrier 
function of HUVEC in culture concluded that activation 
of RhoA was responsible for S1P-induced endothelial 
barrier enhancement [31]. Interestingly, activated RhoA-
Figure 6: CA4P-induced tubulin depolymerisation as well as VE-cadherin redistribution is prevented by S1P. HUVEC 
monolayers were treated with 1 μM CA4P for 4 (A, E), 8 (B, F), or 10 (C, G) minutes then fixed and stained for either tubulin (A-D) or 
VE-cadherin (E-H). HUVEC were also pretreated with 1 μM S1P prior to CA4P treatment; (D,H) show tubulin and VE-cadherin staining 
following S1P pretreatment followed by 10 minutes CA4P treatment. Tubulin disruption and VE-cadherin rearrangement are both evident 
from around 8 minutes post CA4P treatment (arrowheads). Tubulin disruption is pronounced by 10 minutes after starting CA4P treatment 
(*) but tubulin is protected at this timepoint by pretreatment with S1P (**). Scale bars = 5μm.
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Rho kinase is strongly implicated in the damaging effects 
of CA4P on HUVEC [12] and we recently reported that 
in vivo administration of a Rho kinase inhibitor partially 
protected tumour blood vessels against CA4P-induced 
shut-down [13]. It is possible that strong activation of 
the RhoA-Rho kinase pathway by CA4P has damaging 
consequences on endothelial cells, whereas activation of 
this pathway at the endothelial cell periphery by moderate 
doses of S1P elicits more subtle effects, giving rise to local 
activation of the actin cytoskeleton and focal adhesions, 
thereby increasing junctional stability.
Vascular stabilization from investiture of mural cells 
such as pericytes occurs in the tumour microenvironment as 
well as ‘normal’ vasculature. S1P stabilizes vasculature in 
part through its action on N-cadherin, a cell-cell adhesion 
molecule, which is involved in the adhesion of vessel-
stabilizing mural cells to the endothelial cells. Activation of 
N-cadherin via the Gi/Rac1 signalling pathway by binding 
of S1P to S1P1 traffics N cadherin to the cell surface and 
also appears to increase its adhesive properties [32]. Whilst 
we have not extensively examined the relative contributions 
of N-cadherin and mural cells to stabilization of the 
microvasculature in fs120 tumours in the current study, 
our data suggest that CA4P treatment disrupts N-cadherin 
adherens junctions as well as VE-cadherin, and that these 
junctions can also be protected by pre-treatment with S1P.
Figure 7: CA4P disrupts N-cadherin adherens junctions. Untreated co-cultured HUVEC and vSMC stained for CD31 (indicating 
endothelial cells) and N-cadherin (indicating EC/SMC junctions) display mostly intact CD31 and N-cadherin staining at intercellular 
junctions (A, C, E), although some cytoplasmic N-cadherin is also evident. Staining for F-actin in (A) and (B), indicated in red, reveals the 
cytoskeleton of the cells. (A) shows untreated co-cultures in monolayer stained for N-cadherin (green) and actin (red), whilst (B) shows 
CA4P treated cells. (C) shows a tubular structure, typically formed from around 40% of the co-cultured cells, with the rest forming flat 
monolayers as in (E); N-cadherin (red) and CD31 (green). CD31 staining was relatively unaffected by CA4P treatment (green staining in (D) 
and (F) versus (C) and (E)). However, N-cadherin staining appears considerably more intracellular and punctate following CA4P treatment 
(green staining in (B) versus (A) and red staining in (F) versus (E). The change in cellular distribution of N-cadherin following CA4P 
treatment was blocked by pre-treatment with 1μM S1P, allowing N-cadherin to retain its intercellular location, although its appearance 
was less smooth than in untreated cells (red staining in (G) versus (F)). Cells treated with S1P alone also retained intercellular location of 
N-cadherin, but with a less smooth appearance than in untreated cells (red staining in (H) versus (E)). Yellow in merged images indicates 
co-localisation at cell-cell junctions. Arrowheads = EC, asterisks = SMC (revealed by lack of CD31 staining). Scalebars = 15μm.
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Our group has previously shown [26] that fs188 
tumors (counterparts to fs120 tumors that express the 
VEGF188 isoform of VEGF-A in isolation) have a higher 
degree of investiture of pericytes in the microcirculation, 
which is likely to be a major factor in fs188 tumours’ 
relative resistance to CA4P. Stabilisation of N-cadherin 
junctions in the more sensitive fs120 tumours via S1P, 
rendering them less susceptible to CA4P, would support 
this. S1P1 null mice are embryonic lethal, in part due to 
abnormal mural cell coverage of the dorsal aorta [33], 
and S1P1 null embryos display atypical N-cadherin 
localization [34]. It is ligation of S1P to its receptor on 
EC, not mural cells, that plays a role in regulating pericyte 
coverage in neovasculature, [34], and in vitro, S1P binding 
to S1P1 on EC is necessary for EC/pericyte interaction 
[28]. We observed that HUVEC in monoculture alter their 
distribution of N-cadherin following CA4P treatment from 
diffuse and cytoplasmic to more nuclear-concentrated, a 
phenomenon which is blocked by pretreatment with S1P. 
This supports the hypothesis that CA4P does disrupt 
N-cadherin as well as VE-cadherin, and that S1P signaling 
through EC not SMC is important for the regulation of 
N-cadherin localization.
CA4P is primarily a microtubule depolymerizing 
agent, and we questioned whether it had direct effects on 
VE-cadherin or whether the disruption of the VE-cadherin 
complex is secondary to the action of CA4P on tubulin 
of the cytoskeleton. We stained HUVEC monolayers for 
VE-cadherin and tubulin at early timepoints after CA4P 
treatment, and observed that both tubulin disruption 
and early VE-cadherin rearrangement were evident by 
8 minutes of CA4P treatment. From this data we cannot 
be certain which is affected first, and a more detailed 
investigation would be required to elucidate the chain of 
events, but it was of note to find that pretreatment with 
S1P appeared to stabilize tubulin, as well as VE-cadherin, 
against the effects of CA4P. We can only speculate about 
the pathways involved here. As noted above, signaling 
through the S1P receptors following ligation of S1P 
plays a significant role in regulation of the Rho family of 
GTPases, part of the Ras superfamily of small GTPases 
[35]. Rac1, a member of the Rho family, is activated by 
ligation of S1P to S1PR1 in HUVEC [22, 36]. This can 
lead to phosphorylation of stathmin [37], a process that 
inhibits stathmin’s role in microtubule destabilization [38], 
39]. Alternatively, S1P-mediated activation of N-cadherin 
has been shown to induce microtubule polymerization in 
EC via a Rac1 pathway [26]. It is conceivable that S1P has 
vessel-stabilising effects by both activating N-cadherin, 
thereby strengthening intercellular interactions, and by 
preventing microtubule destabilization.
Altogether our data suggests that an important 
component of the VDA CA4P’s activity is disruption of 
VE- and N-cadherin complexes at inter-endothelial cell 
and EC/mural cell junctions, rendering the vessels prone 
to haemorrhage and shut-down. Abnormalities of these 
junctions in tumors could at least partly explain the relative 
susceptibility of tumour versus normal tissue blood vessels 
to CA4P. S1P has a protective effect on both adherens 
junctional proteins as well as the cytoskeletal protein 
tubulin, and in vivo, protects tumour microvasculature 
against the effects of CA4P. Therefore, antagonism of S1P 
receptors, in order to diminish the effects of endogenous 
S1P at the tumour site, may improve the CA4P induced 
disruption of the microvasculature. Further studies of this 




All experiments were conducted in accordance with 
the United Kingdom Home Office Animals (Scientific 
Procedures) Act 1986, local ethical approval and following 
the UK National Cancer Research Institute’s Guidelines 
for the Welfare and Use of Animals in Cancer Research 
[40].
Cell culture
HUVEC (Promocell, Heidelberg, Germany) were 
cultured on gelatin-coated tissue culture plastics with 
endothelial cell basal medium (Promocell, Heidelberg, 
Germany), supplemented with 10% foetal calf serum, 4 μl/
ml endothelial cell growth supplement, 0.1 ng/ml human 
epidermal growth factor, 1 ng/ml human basic fibroblast 
growth factor, and 1 μg/ml hydrocortisone (all Promocell, 
Heidelberg, Germany). Media were replaced every 
two days and cells subcultured just before confluence. 
HUVEC used in experiments were between passages 3-5. 
For co-culture of HUVEC and SMC, HUVEC (as above) 
and Human Vascular Smooth Muscle Cells (Promocell, 
Heidelberg, Germany) were seeded at a 50:50 ratio into 
8-chamber slides, 1 x 105 cells per 400 μl per chamber in 
media as above. Cultures grew for 3 days.
HUVEC permeability assay
Methods were as described previously [12]. Cell 
culture filter inserts with a 3 μm pore size (BD Falcon, 
Oxford, UK) were placed inside 24 well tissue culture 
plates and coated with 0.2% gelatin (Sigma-Aldrich, 
Dorset, UK) in PBS for 30 min. HUVEC were plated 
inside the filters at a density of 105 cells per insert in 200 
μl medium. 700 μl medium was added to each lower 
chamber and the cells incubated at 37°C, 5% CO2 until 
confluent. Cells were treated with either S1P (Biomol, 
Exeter, UK) or S1P vehicle (7% methanol in PBS) by 
directly adding the drugs to the medium for 30 min, at 
which time CA4P, kindly provided by OxiGene Inc. (now 
Mateon Therapeutics) or vehicle (PBS) were added. After 
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a further 60 min, media was carefully removed from the 
inserts to avoid damage to the monolayers and replaced 
with medium containing 0.8 mg/ml 70kDa FITC-Dextran 
(Sigma-Aldrich, Dorset, UK). The filters were placed 
into new wells containing 700 μl fresh medium and 
plates returned to the incubator for 30 min. The filters 
were then removed from the wells, contents of the lower 
wells mixed and fluorescence read using a plate reader 
(FluoStar) at excitation 485 nm, emission 520 nm. As 
controls, passage of FITC-Dextran through untreated 
monolayers and gelatin-coated filters without cells were 
measured. HUVEC were seeded onto gelatin-coated 12-
well tissue culture plates and treated in parallel with S1P/
CA4P or vehicle in order to visualise the changes to the 
monolayers. Experiments were performed in triplicate 
and repeated three times. Images were acquired using a 
Nikon Eclipse TS100 microscope and Nikon Coolpix 995 
camera.
In vivo treatment with S1P/CA4P
Fs120 cells (1 x 106 cells in 0.05ml) were 
injected subcutaneously into the dorsal sub-cutis of 
severe combined immunodeficiency (SCID) mice 
under isofluorane anaesthesia. Tumours were allowed 
to develop until they reached ~6mm diameter. In order 
to measure changes in tumour perfusion during S1P/
CA4P treatment, relative changes in volumetric tumour 
microvascular red cell flux were measured using the 
OxyfloTM laser Doppler perfusion system (Oxford 
Optronix Ltd, Oxford, UK). Group sizes were powered 
towards detecting a difference between perfusion effects 
of CA4P alone and CA4P combined with administration 
of S1P. An intraperitoneal CA4P dose of 30 mg/kg was 
chosen as this was found previously to cause a significant 
drop in blood flow in fs120 tumours [41]. Fs120 
tumour-bearing mice were weighed and restrained. An 
intravenous (i.v) cannula was inserted into the tail vein, 
then the mice were anaesthetised with isoflurane whilst 
restrained on a heat pad, thermostatically-controlled via 
a rectal probe, for the remainder of the experiment. Four 
fibre optic laser Doppler probes were inserted into each 
tumour, and baseline readings of blood perfusion units 
(BPU) obtained for ~20 minutes until stable readings 
were obtained. Throughout the experiment BPU were 
recorded every 5 minutes. S1P (at 8mg/kg/hr for 20 
mins followed by 2mg/kg/hr for 40 minutes) or vehicle 
(7% methanol in PBS/4% bovine serum albumin for 
20 minutes then 1.5% methanol in PBS/4% bovine 
serum albumin for 40 minutes) was then administered 
via an i.v line. 30 mins after starting infusion of S1P, a 
single bolus of CA4P (30mg/kg in heparinised saline) 
or vehicle (0.3ml of heparinised saline) was injected via 
an intraperitoneal (i.p) line. After a further 30 minutes 
the S1P infusion was stopped (1 h total) and the cannula 
flushed through with saline.
After a further 30 minutes (60 min after injection of 
CA4P) 0.2 mg FITC-conjugated Lycopersicon esculentum 
tomato lectin (Vector Laboratories, Peterborough, UK) 
per mouse was injected 5 min before killing to detect 
perfused blood vessels at the time of lectin injection. The 
animals were then killed by an i.v. overdose of sodium 
pentobarbitone. BPU were recorded for a further 5 minutes 
to obtain end-baseline readings. For analysis of BPU, 
results were discarded from any probes which showed 
inconsistent readings or readings <100. End-baseline 
readings for each probe were subtracted from probe 
readings taken throughout the experiment. Data were 
expressed as a percentage of the pre-treatment value and 
individual probe readings were averaged at each time point 
to obtain a single timeline of results for each tumour, which 
were used for statistical analysis. Means ± SEM of these 
single timelines were plotted in Figure 2. Immediately 
following completion of the experiment, the mice were 
perfused transcardially with 1% paraformaldehyde (PFA) 
for 2 minutes. The tumours were excised, and half snap 
frozen for lectin analysis. The other half was placed in 
1% PFA for 1 hr then transferred to a sucrose solution for 
overnight refrigeration prior to processing and embedding 
for subsequent immunofluorescence studies.
Immunofluorescence and immunohistochemistry
To stain VE-cadherin or tubulin on HUVEC, 
HUVEC (Promocell, Heidelberg, Germany) up to passage 
5 were grown on gelatin coated 4-chamber slides (Lab-
Tek, Nunc, Rochester, New York) to confluence. Cells 
were fixed in 3.7% formalin in HBSS, washed in PBS, 
permeabilised in PBS/0.1% Triton-x100 for 5 minutes 
then washed again in PBS. Slides were then blocked at 
room temperature for 1h with PBS containing 2% BSA 
and 5% goat serum, then incubated overnight at 4°C with 
mouse anti-human CD144 (555661, BD Pharmingen, 
Oxford, UK) or mouse anti-human tubulin (T4025, Sigma-
Aldrich, Dorset UK) at 1:200 in blocking solution. The 
following day slides were washed in PBS then incubated 
with biotinylated goat anti-mouse antibody (Vector 
Laboratories, Peterborough, UK) at 1:100 in blocking 
buffer for 1h at room temperature. Slides were washed 
again then incubated with fluorescein avidin (Vector 
Laboratories, Peterborough, UK) at 1:250 plus Texas Red 
phalloidin (Invitrogen, Carlsbad, USA) in 10 mM HEPES, 
pH 7.5, 0.15M NaCl for 1h at room temperature. Finally 
slides were washed in PBS then mounted in Vectashield 
with DAPI (Vector Laboratories, Peterborough, UK). 
Images were acquired using a LeicaDMI4000B inverted 
microscope and LSAF software. For visualization of 
VE cadherin in HUVEC cells following S1P or CA4P 
treatment, cells were pre-treated with either S1P (1 μM) or 
vehicle (7% MeOH) for 30 minutes, at which point CA4P 
(1 μM) or PBS was added to the media for the appropriate 
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time. Cells were fixed in 3.7% formalin in HBSS, then 
stained using an antibody against VE-cadherin as above.
For double staining of N-cadherin and CD31, the 
general staining protocol as above was followed. S1P/
CA4P treated cells were incubated overnight at 4oC with 
a cocktail of primary antibodies (mouse anti human 
N-cadherin BD610920 (BD Pharmingen, Oxford, UK) and 
rabbit anti CD31 (BD Pharmingen, Oxford, UK) at 1:100 
per antibody. The following day cells were incubated for 
1h with a cocktail of secondary antibodies (Alexafluor 
488 goat anti rabbit (Invitrogen, Carlsbad, USA) and 
biotinylated goat anti mouse (Vector Laboratories, 
Peterborough, UK)) at 1:200, then, after washing, for a 
further 1h with Texas Red streptavidin at 1:200 (Vector). 
Slides were mounted using Vectashield with DAPI (Vector 
Laboratories, Peterborough, UK).
To calculate the tumour perfusion index, frozen 
tumours were sectioned to 10μm thick and immunostained 
for platelet endothelial cell adhesion molecule (CD31), 
using Alexa-Fluor 555 for visualization, to detect both 
perfused and unperfused blood vessels. Detailed methods 
for staining and image capture are described in Williams 
et al [13]. Individual captured images were analysed using 
in-house- developed Matlab-based software. Fluorescence 
channels were manually thresh-holded for each individual 
tumour. The perfusion index for each image was calculated 
as the number of pixels positive for FITC (from FITC-
lectin) as a percentage of the number of pixels positive for 
Alexa-Fluor 555.
To visualize VE-cadherin on ex vivo tumour sections, 
80 μm thick sections were stained. Rat anti-mouse CD144, 
(BD Pharmingen, BD550548, Oxford, UK) at 1:100 was 
incubated overnight in Immunomix (0.3% Triton X-100, 
0.1% sodium azide, 0.2% bovine serum albumin in PBS) 
containing 1% normal goat serum. A fluorescent secondary 
antibody (AlexaFluor goat anti-rat 555, Invitrogen, Carlsbad, 
USA), was incubated at room temperature for 5 hours. 
Images were acquired using a Zeiss LSM510 NLO inverted 
confocal microscope with a x80 objective. Areas of intact 
VE-cadherin or disruption (5 images per tumour) as judged 
by areas of smooth staining (intact) or disjointed staining 
(disruption) were measured using pixel area measurement 
tools in Photoshop (Adobe). All image acquisition and 
analysis was performed blind to treatment group.
Flow cytometry
HUVEC were treated with 1 μM CA4P for 60 min 
+/- 30 min 1 μM S1P pre-treatment. Following treatment 
cells were washed in PBS then detached using 2 mM 
EDTA at 37°C for 15-20 minutes. Cell suspensions were 
collected, washed twice in PBS then resuspended in ice-
cold Immunomix containing mouse anti-human CD144 
(BD Pharmingen, BD555661) antibody at a dilution of 
1:100. Cells were incubated at 4°C for 1 h, then washed 
twice and resuspended in ice cold Immuonomix containing 
Alexafluor 555 (Invitrogen) at 1:200. Cells were incubated 
at 4°C for 30 mins then washed twice in cold PBS and 
resuspended in 300 ul cold PBS before analysis on an 
LSRII FACS machine (BD).
Statistics
Results from HUVEC monolayer experiments were 
tested for significant differences using a one-way ANOVA 
with a post-hoc Tukey test. A 2-way ANOVA, with 
repeated measures and a post-hoc Tukey test was used 
for Laser Doppler flowmetry results. Tumour perfusion 
results were tested with an unpaired Students t-test. All 
tests were carried out using GraphPad Prism 6 software for 
Mac OS X (GraphPad Software Inc., San Diego, USA). 
In all cases, differences between treatment groups were 
described as significant if the probability corresponding to 
the relevant statistic was less than 0.05.
Abbreviations
BPU (blood perfusion units), CA4P (Combretastatin 
A-4 phosphate), EC (endothelial cells), fs (fibrosarcoma), 
FACS (fluorescence activated cell sorting), HBSS (Hanks 
balanced salt solution), HUVEC (human umbilical vein 
endothelial cells), PBS (phosphate buffered saline), 
SMC (smooth muscle cells), SCID (severe combined 
immunodeficiency), S1P (Sphingosine-1-phosphate), VDA 
(vascular disrupting agent), vSMC (vascular smooth muscle 
cells), VE-cadherin (vascular endothelial cadherin), VEGF 
(vascular endothelial growth factor).
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